Mostafa Allahyari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mostafa Allahyari has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Hossein Fallah
Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Athena Rajaie
Department of Clinical Biochemistry, Afzalipour School of Medicine , Kerman University of Medical Sciences , Kerman 7616913555 , Iran
1 shared publication - Beydolah Shahouzehi
Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Saeedeh Moinaldini
Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication
Latest Publications
- Open Access
- 1 May 2023
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 28 (2) , 1-11
Evaluation of the effect of interleukin-1 receptor associated kinase (IRAK) inhibitor on PPAR.γ and GLUT.4 genes expression in muscle tissueof insulin resistant mice
Background and Aim: Diabetes mellitus is a metabolic disorder with an increasing prevalence in the world. Obesity plays a pivotal role in increasing the risk of diabetes, metabolic syndrome, hypertension and cardiovascular diseases. Obesity dependent mild-inflammation leads to an imbalance in the secretion of adipokines and thereby reduces insulin sensitivity. The TLR ...
- 1 May 2023
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 28 (2) , 1-11
Open AccessEvaluation of the effect of interleukin-1 receptor associated kinase (IRAK) inhibitor on PPAR.γ and GLUT.4 genes expression in muscle tissueof insulin resistant mice
Background and Aim: Diabetes mellitus is a metabolic disorder with an increasing prevalence in the world. Obesity plays a pivotal role in increasing the risk of diabetes, metabolic syndrome, hypertension and cardiovascular diseases. Obesity dependent mild-inflammation leads to an imbalance in the secretion of adipokines and thereby reduces insulin sensitivity. The TLR ...
- Open Access
- 1 December 2020
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 14 (6) , 253-260
IRAK inhibitor can improve insulin sensitivity in insulin-resistant mice fed with a high-fat diet
Background: Obesity and the inflammation associated with it, play a key role in the development of insulin resistance through the release of inflammatory cytokines and free fatty acids and the stimulation of toll-like receptors (TLR). Interleukin-1 receptor-associated kinase (IRAK), which mediates the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, is an important molecule in TLR signaling. The NF-κB pathway can reduce insulin efficacy by increasing the expression of proinflammatory cytokines. There is no safe inhibitor for the NF-κB pathway, and for this reason, the upper mediator of this pathway was selected for investigation. Objectives: To determine the effects of an IRAK inhibitor on insulin resistance and serum biochemical factors in high-fat-fed insulin-resistant mice. Methods: Insulin resistance was developed in C57BL/6J mice by 12 weeks of a high-fat diet. Subsequently, the IRAK 1/4 inhibitor 1-(2-(4-morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole (IRAKi)/or pioglitazone, or both, were administered for a further 2 weeks. After 12 h fasting, blood and tissue samples were collected, insulin and glucose levels were assayed, and the homeostatic model assessment was used to quantify insulin resistance (HOMA-IR). Results: The IRAKi decreased blood glucose levels significantly (253 ± 14.3 mg/dL vs 390.1 ± 16.6 mg/dL) and increased insulin sensitivity compared with untreated controls. However, we did not find a synergistic effect of IRAKi with pioglitazone in increasing insulin sensitivity. Conclusion: IRAKis can increase insulin sensitivity and their efficacy is comparable to pioglitazone. However, combined administration of pioglitazone and IRAKi had no synergistic effect compared with monotherapy.
- 1 December 2020
- Published by Walter de Gruyter GmbH in Asian Biomedicine
- Vol. 14 (6) , 253-260
Open AccessIRAK inhibitor can improve insulin sensitivity in insulin-resistant mice fed with a high-fat diet
Background: Obesity and the inflammation associated with it, play a key role in the development of insulin resistance through the release of inflammatory cytokines and free fatty acids and the stimulation of toll-like receptors (TLR). Interleukin-1 receptor-associated kinase (IRAK), which mediates the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, is an important molecule in TLR signaling. The NF-κB pathway can reduce insulin efficacy by increasing the expression of proinflammatory cytokines. There is no safe inhibitor for the NF-κB pathway, and for this reason, the upper mediator of this pathway was selected for investigation. Objectives: To determine the effects of an IRAK inhibitor on insulin resistance and serum biochemical factors in high-fat-fed insulin-resistant mice. Methods: Insulin resistance was developed in C57BL/6J mice by 12 weeks of a high-fat diet. Subsequently, the IRAK 1/4 inhibitor 1-(2-(4-morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole (IRAKi)/or pioglitazone, or both, were administered for a further 2 weeks. After 12 h fasting, blood and tissue samples were collected, insulin and glucose levels were assayed, and the homeostatic model assessment was used to quantify insulin resistance (HOMA-IR). Results: The IRAKi decreased blood glucose levels significantly (253 ± 14.3 mg/dL vs 390.1 ± 16.6 mg/dL) and increased insulin sensitivity compared with untreated controls. However, we did not find a synergistic effect of IRAKi with pioglitazone in increasing insulin sensitivity. Conclusion: IRAKis can increase insulin sensitivity and their efficacy is comparable to pioglitazone. However, combined administration of pioglitazone and IRAKi had no synergistic effect compared with monotherapy.